The European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) have set up a new ‘cluster’ on rare diseases to share experiences and best practices on each other’s regulatory approach to the development of medicines for these diseases.
The agencies will exchange information on various aspects of the development and scientific evaluation of medicines for rare diseases. These include topics such as:
- the design of clinical trials in small populations and the use of statistical analysis methods;
- the selection and validation of trial endpoints, i.e. target outcomes of a trial;
- preclinical evidence to support development programmes;
- the design of post-marketing studies, in particular in the context of early access mechanisms such as EMA’s conditional marketing authorisation and FDA’s accelerated approval;
- risk management strategies for long-term safety issues with medicines for rare diseases.
The cluster will provide a forum for confidential exchange of draft documents, policies under development, and more detailed information supporting the scientific basis for decision making on medicine development.
More information: Press release